Triple combination cancer immunotherapy improves outcomes in preclinical melanoma model

In adoptive cell transfer immunotherapy, T cells able to recognize a tumor are harvested, expanded in the laboratory, and then reintroduced to attack the tumor. However, they often do not persist long enough to finish the job. A triple combination regimen of adoptive T cell transfer, a PIM kinase inhibitor, and a PD1 inhibitor improved T cell persistence and tumor control in a mouse model of melanoma, report investigators.

from Latest Science News -- ScienceDaily https://ift.tt/2P9EC9h

Comments

Popular posts from this blog

Jared Leto Was Responsible for the "We Live in a Society" Line in the 'Zack Snyder's Justice League' Trailer - /FILM

How to keep Amazon, Apple, and Google from listening to your Alexa, Siri, and Assistant recordings - TechHive

Exclusive: IAEA found uranium traces at Iran 'atomic warehouse' - diplomats - Reuters